射干合剂治疗急性上呼吸道感染的临床研究

Clinical Study on “Shegan Mixture” in the Treatment of Acute Upper Respiratory Tract Infection

目的:评价射干合剂治疗急性上呼吸道感染的临床疗效,探讨射干合剂的适应证。方法:将246例风热犯肺或痰热壅肺型急性上呼吸道感染患者随机分为射干合剂组、宣肺止嗽组及厄多司坦组,每组各82例。所有患者均给予抗菌、抗病毒等常规治疗,在此基础上射干合剂组加服射干合剂,宣肺止嗽组加服宣肺止嗽合剂,厄多司坦组加服厄多司坦片。各组疗程均为7 d。评价三组患者的临床疗效及中医证候评分的变化。结果:(1)射干合剂组、宣肺止嗽组、厄多司坦组的临床总有效率分别为92.68%、83.75%和76.32%,三组间比较差异有统计学意义(P<0.05),射干合剂组疗效优于宣肺止嗽组、厄多司坦组(P<0.05),而宣肺止咳组与厄多司坦组组间比较差异无统计学意义(P>0.05)。(2)治疗后,三组患者的中医证候评分较治疗前均显著降低(P<0.01),且射干合剂组的证候评分治疗前后差值显著高于宣肺止嗽组、厄多司坦组(P<0.01)。结论:射干合剂治疗风热犯肺或痰热壅肺型急性上呼吸道感染疗效较佳,可显著改善患者的临床症状和中医证候。

Objective： To evaluate the clinical effects of ＂Shegan Mixture＂ in the treatment of acute upper respiratory tract infection and investigate the indications of ＂Shegan Mixture＂. Methods： Two hundred and forty-six cases of acute upper respiratory tract infection with wind-heat invading lung syndrome or phlegm-heat obstructing lung syndrome were randomly divided into the ＂Shegan Mixture＂ group, ＂Xuanfei Zhisou Mixture＂ group and erdosteine group, 82 cases in each group. All the patients were given conventional treatment such as antibacterial and antiviral therapy. Based on above, the patients in the ＂Shegan Mixture＂ group were treated with ＂Shegan Mixture＂, the patients in the ＂Xuanfei Zhisou Mixture＂ group were treated with ＂Xuanfei Zhisou Mixture＂ and the patients in the erdosteine group were treated with erdosteine tablet. The treatment course was 7 days. The clinical effect and the scores of Chinese medical syndrome were evaluated. Results： （1）The clinical total effective rates of ＂Shegan Mixture＂ group, ＂Xuanfei Zhisou Mixture＂ group and erdosteine group were 92.68%, 83.75% and 76.32% respectively, with statistical difference among the three groups （ P 〈 0. 05 ）, and the effect of the ＂Shegan Mixture＂ group was superior to the ＂Xuanfei Zhisou Mixture＂ group and erdosteine group （P 〈 0.05 ）, while there was no statistical difference between the ＂ Xuanfei Zhiseu Mixture＂ group and erdosteine group （ P 〉 0.05 ）. （2） After treatment, the scores of Chinese medical syndrome in the three groups were all obviously decreased （ P 〈 0.01 ） , and the Dvalue of the syndrome scores between before and after treatment in the ＂Shegan Mixture＂ group was higher than that in the ＂Xuanfei Zhisou Mixture＂ group and erdosteine group （P 〈 0.01 ）. Conclusion： ＂Shegan Mixture＂ shows good effect in the treatment of acute upper respiratory tract infection with wind-heat invading lung syndrome or phlegm-heat obstructing lung syndrome and can significantly improve the clinical symptoms and Chinese medical syndrome.